Quintiles Transitional Holdings Inc. (NYSE:Q) Director Dennis B. Ph D. Gillings sold 968,023 shares of the stock in a transaction dated Monday, August 28th. The shares were sold at an average price of $97.33, for a total value of $94,217,678.59. Following the completion of the transaction, the director now directly owns 9,071,839 shares in the company, valued at approximately $882,962,089.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Quintiles Transitional Holdings Inc. (NYSE Q) traded down 0.16% during mid-day trading on Thursday, hitting $95.64. The stock had a trading volume of 769,245 shares. Quintiles Transitional Holdings Inc. has a 1-year low of $70.10 and a 1-year high of $99.95. The stock has a market cap of $20.71 billion, a PE ratio of 277.22 and a beta of 0.64. The firm’s 50-day moving average price is $91.06 and its 200-day moving average price is $84.68.

Quintiles Transitional Holdings (NYSE:Q) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.04. Quintiles Transitional Holdings had a return on equity of 14.23% and a net margin of 0.82%. The company had revenue of $1.97 billion for the quarter, compared to the consensus estimate of $1.96 billion. During the same quarter last year, the business posted $0.93 earnings per share. The firm’s revenue was up 68.7% compared to the same quarter last year. On average, equities analysts expect that Quintiles Transitional Holdings Inc. will post $4.58 earnings per share for the current year.

Quintiles Transitional Holdings announced that its Board of Directors has initiated a share buyback program on Wednesday, May 24th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 5.4% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: “Quintiles Transitional Holdings Inc. (Q) Director Dennis B. Ph D. Gillings Sells 968,023 Shares” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/quintiles-transitional-holdings-inc-q-director-dennis-b-ph-d-gillings-sells-968023-shares/1534591.html.

Several large investors have recently modified their holdings of Q. Fiduciary Trust Co. acquired a new stake in shares of Quintiles Transitional Holdings during the second quarter worth about $105,000. Global X Management Co. LLC increased its stake in shares of Quintiles Transitional Holdings by 30.8% in the first quarter. Global X Management Co. LLC now owns 1,469 shares of the medical research company’s stock worth $118,000 after buying an additional 346 shares during the period. GWM Advisors LLC acquired a new stake in shares of Quintiles Transitional Holdings during the second quarter worth about $122,000. Korea Investment CORP increased its stake in shares of Quintiles Transitional Holdings by 142.5% in the second quarter. Korea Investment CORP now owns 1,370 shares of the medical research company’s stock worth $123,000 after buying an additional 805 shares during the period. Finally, IFP Advisors Inc increased its stake in shares of Quintiles Transitional Holdings by 187.1% in the first quarter. IFP Advisors Inc now owns 1,774 shares of the medical research company’s stock worth $143,000 after buying an additional 1,156 shares during the period. Institutional investors own 91.36% of the company’s stock.

Several equities analysts have weighed in on the company. Barclays PLC reissued an “overweight” rating and issued a $98.00 target price (up previously from $90.00) on shares of Quintiles Transitional Holdings in a research note on Monday, July 17th. William Blair raised Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $70.10 to $93.42 in a research report on Friday, August 4th. Jefferies Group LLC reaffirmed a “hold” rating and set a $94.00 price target on shares of Quintiles Transitional Holdings in a research report on Friday, August 4th. Citigroup Inc. raised their price target on Quintiles Transitional Holdings from $96.00 to $97.00 and gave the stock a “neutral” rating in a research report on Monday, August 7th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $92.00 price target (up previously from $87.00) on shares of Quintiles Transitional Holdings in a research report on Friday, August 4th. Eleven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $90.25.

Quintiles Transitional Holdings Company Profile

Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.

Insider Buying and Selling by Quarter for Quintiles Transitional Holdings (NYSE:Q)

Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.